Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Novel test could help get best treatment for advanced bowel cancer patients

Novel test could help get best treatment for advanced bowel cancer patients

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

New combination treatment approved by FDA for metastatic pancreatic cancer

New combination treatment approved by FDA for metastatic pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Research provides insights into the ability of FL118 to overcome treatment resistance

Research provides insights into the ability of FL118 to overcome treatment resistance

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer